Sublingual İmmünoterapi

Year 2006, Volume: 4 Issue: 1, 137 - 139, 01.04.2006

Cevdet Özdemir Narin Nadir Bahçeciler İşıl Berat Barlan

Abstract

Son yıllarda astım ve alerjik hastalıkların görülme sıklığı giderek artmaktadır 1 . Ülkemizde de bu artışa paralel bir eğilim gözlemlenmektedir 2-6 . Günümüzde alerjenden kaçınmanın yanısıra son yıllarda inhale kortikosteroidlerin gerek çocukluk çağında, gerekse erişkin astımında yoğun olarak kullanılması ile astım klinik olarak kontrol altında tutulabilmektedir 7 .

References

• 1. Sennhauser FH, Braun-Fahrlander C, Wildhaber JH. The burden of asthma in children: a European perspective. Paediatr Respir Rev 2005;6:2-7.
• 2. Saraclar Y, Kuyucu S, Tuncer A, Sekerel B, Sackesen C, Kocabas C. Prevalence of asthmatic phenotypes and bronchial hyperresponsiveness in Turkish schoolchildren: an International Study of Asthma and Allergies in Childhood (ISAAC) phase 2 study. Ann Allergy Asthma Immunol 2003; 91:477-84.
• 3. Canitez Y, Sapan N. The prevalence of asthma, allergic rhinitis, and eczema in Bursa, Turkey: An ISAAC study. J Allergy Clin Immunol 2000; 105:S318.
• 4. Ones U, Sapan N, Somer A, et al. Prevalence of childhood asthma in Istanbul, Turkey. Allergy 1997; 52:570-75.
• 5. Bayram I, Guneser Kendirli S, et al. The prevalence of asthma and allergic diseases in children of school age in Adana in southern Turkey. Turk J Pediatr 2004; 46:221-5.
• 6. Bahceciler NN, Ozdemir C, Arikan C, et al. Prevalence of asthma and its risk factors in an underdeveloped region of Istanbul. Allergy 2002; 57:S73,p189.
• 7. Canonica GW. Treating asthma as an inflammatory disease. Chest 2006; 130:21-8.
• 8. Meltzer EO. Allergic rhinitis:managing the pediatric spectrum. Allergy Asthma Proc 2006; 27:2-8.
• 9. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician's perception. Chest 2006; 130:41-53.
• 10. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergenspecific immunotherapy. Nature Rev 2006; 6:761-71.
• 11. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1572-3.
• 12. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;4:CD001186.
• 13. Pagno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-7.
• 14. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhino conjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
• 15. Durham S, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
• 16. Passalacqua G, Guerra L, Pasquali M, Canonica GW. Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets 2006; 5:43-51.
• 17. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
• 18. Akdis CA, Barlan IB, Bahceciler N, Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy 2006;61 Suppl 81:11-4.
• 19. Allam JP, Niederhagen B, Bucheler M,Appel T, Betten H, Bieber T et al. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 2006; 61:166-72.
• 20. Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P, Mistrello G, Canonica GW. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997; 100:122-9.
• 21. Akdis CA, Blaser K, Akdis M. Mechanisms of allergen-specific immunotherapy. Chem Immunol Allergy 2006; 91:195-203.
• 22. Till SJ, Francis JN, Nouri-Aria K, Durham S. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-34.
• 23. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-12.
• 24. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:1162-72.
• 25. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32:49-55.
• 26. Bahceciler NN, Arikan C, Taylor A, Akdis M, Blaser K, Barlan IB, Akdis CA.. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136:287-94.
• 27. Özdemir C. Ev tozu akar›na duyarl› persistan ast›ml› çocuklarda sublingual immunoterapinin hastal›¤›n do¤al seyri üzerine etkisi. (Alerji Yandal Tezi). ‹stanbul. Marmara Üniversitesi. 2004.
• 28. Moingeon P. Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy 2006;61Suppl 81:15-9.
• 29. Lowenstein H, Larsen JN. Recombinant allergens/allergen standardization. Curr Allergy Asthma Rep 2001; 1:474-9.
• 30. van Ree R, Dorpema JW, Vieths S. Allergy vaccines: a need for standardisation in mass units of major allergen. Pharmeuropa Bio 2005; 2005:27-30.
• 31. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33:206-10.
• 32. Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingualswallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121:229-34.